Role of N‐glycosylation in EGFR ectodomain ligand binding

Abstract

The epidermal growth factor receptor (EGFR) is a tyrosine kinase protein, overexpressed in several cancers. The extracellular domain of EGFR is known to be heavily glycosylated. Growth factor (mostly epidermal growth factor or EGF) binding activates EGFR. This occurs by inducing the transition from the autoinhibited tethered conformation to an extended conformation of the monomeric form of EGFR and by stabilizing the flexible preformed dimer. Activated EGFR adopts a back-to-back dimeric conformation after binding of another homologous receptor to its extracellular domain as the dimeric partner. Several antibodies inhibit EGFR by targeting the growth factor binding site or the dimeric interfaces. Glycosylation has been shown to be important for modulating the stability and function of EGFR. Here, atomistic MD simulations show that N-glycosylation of the EGFR extracellular domain plays critical roles in the binding of growth factors, monoclonal antibodies, and the dimeric partners to the monomeric EGFR extracellular domain. N-glycosylation results in the formation of several noncovalent interactions between the glycans and EGFR extracellular domain near the EGF binding site. This stabilizes the growth factor binding site, resulting in stronger interactions (electrostatic) between the growth factor and EGFR. N-glycosylation also helps maintain the dimeric interface and plays distinct roles in binding of antibodies to spatially separated epitopes of the EGFR extracellular domain. Analysis of SNP data suggests the possibility of altered glycosylation with functional consequences. Proteins 2017; 85:1529-1549. © 2017 Wiley Periodicals, Inc.

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death

“…EGFR has a complex mechanism of regulation involving receptor oligomerization, lipid raft localization, shedding, and dynamic partitioning between cellular compartments including the plasma membrane, endosome and nucleus [ 42 – 45 ]. Many of these processes are known to be influenced by EGFR glycan composition [ 39 , 46 – 48 ]. Furthermore, glycosylation modulates the overall conformation of EGFR in the absence of ligand binding.…”

Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation

“…The extracellular domain of EGFR is heavily N -glycosylated and the glycosylation pattern is implicated in receptor dimerization and subsequent activation 53,54 . Interestingly, the crystal structure of Chi3l3 revealed a saccharide-binding site 55 and functional studies showed that Chi3l3 exhibited binding specificity to saccharides with free amine groups, including glucosamine (GlcN) and GlcN-polymers 56 , making it compatible with binding to EGFR.…”

The EGFR odyssey – from activation to destruction in space and time

“…Specificity of EGFR activation is mediated through the establishment of defined contacts between the ligand and the binding groove of the receptor located on its extracellular face (Bajaj et al, 1987;Lax et al, 1988;Ferguson et al, 2003;Jorissen et al, 2003;Zhu et al, 2017). Variations in sidechain features between different ligands, as well as posttranslational modifications present on the extracellular EGFR domain, determine the strength of engagement (Azimzadeh Irani et al, 2017). Solid-state nuclear magnetic resonance (NMR) experiments have demonstrated that, in the absence of ligand, the intracellular region of EGFR exists in a rigid conformation, while the extracellular domain remains highly dynamic.…”